Ensysce Biosciences, Inc.ENSCEarnings & Financial Report
Nasdaq
NextMar 19, 2026
ENSC Q3 2025 Key Financial Metrics
Revenue
$493.1K
Gross Profit
N/A
Operating Profit
$-3.7M
Net Profit
$-3.7M
Gross Margin
N/A
Operating Margin
-758.7%
Net Margin
-756.3%
YoY Growth
-85.6%
EPS
$-1.29
Financial Flow
Ensysce Biosciences, Inc. Q3 2025 Financial Summary
Ensysce Biosciences, Inc. reported revenue of $493.1K for Q3 2025, with a net profit of $-3.7M (-756.3% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $493.1K |
|---|---|
| Net Profit | $-3.7M |
| Gross Margin | N/A |
| Operating Margin | -758.7% |
| Report Period | Q3 2025 |
Ensysce Biosciences, Inc. Annual Revenue by Year
Ensysce Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $5.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $5.2M |
| 2023 | $2.2M |
| 2022 | $2.5M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $515033 | $305722 | $181797 | $3.4M | $1.3M | $1.3M | $1.4M | $493104 |
| YoY Growth | -64.1% | -61.3% | -62.9% | 685.3% | 153.1% | 331.7% | 654.4% | -85.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.7M | $5.1M | $2.8M | $9.4M | $5.6M | $4.6M | $5.6M | $3.2M |
| Liabilities | $3.4M | $1.7M | $1.3M | $2.8M | $2.2M | $1.9M | $2.5M | $2.3M |
| Equity | $-322858 | $3.7M | $1.8M | $6.9M | $3.7M | $3.0M | $3.4M | $1.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.8M | $-3.4M | $-2.3M | $-1.0M | $-764090 | $-1.7M | $-2.7M | $-1.9M |